Efficacy and safety of nivolumab in routine NSCLC treatment - an observational study in 5 lung cancer centers in Berlin, Germany

Conclusion: The use of nivolumab in routine NSCLC treatment shows promising efficacy consistent to the results of randomised clicinal trials. Despite a similar spectrum of irAE, therapy-related deaths occurred in our cohort. Thus, good selection and close monitoring is just as essential in routine care patients.

Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Misch, D., de Wit, M., Grah, C., Grohe, C., Kollmeier, J., Blum, T., Frost, N., Reinecke, A. Tags: Lung Cancer Source Type: research